Routine application of the Lymph2Cx assay for the subclassification of aggressive B-cell lymphoma: report of a prospective real-world series
Please always quote using this URN: urn:nbn:de:bvb:20-opus-324686
- The subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5\(^{th}\) edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. ThisThe subclassification of diffuse large B-cell lymphoma (DLBCL) into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes has become mandatory in the 2017 update of the WHO classification of lymphoid neoplasms and will continue to be used in the WHO 5\(^{th}\) edition. The RNA-based Lymph2Cx assay has been validated as a reliable surrogate of high-throughput gene expression profiling assays for distinguishing between GCB and ABC DLBCL and provides reliable results from formalin-fixed, paraffin-embedded (FFPE) material. This test has been previously used in clinical trials, but experience from real-world routine application is rare. We routinely applied the Lymph2Cx assay to day-to-day diagnostics on a series of 147 aggressive B-cell lymphoma cases and correlated our results with the immunohistochemical subclassification using the Hans algorithm and fluorescence in situ hybridization findings using break-apart probes for MYC, BCL2, and BCL6. The routine use of the Lymph2Cx assay had a high technical success rate (94.6%) with a low rate of failure due to poor material and/or RNA quality. The Lymph2Cx assay was discordant with the Hans algorithm in 18% (23 of 128 cases). Discordant cases were mainly classified as GCB by the Hans algorithm and as ABC by Lymph2Cx (n = 11, 8.6%). Only 5 cases (3.9%) were classified as non-GCB by the Hans algorithm and as GCB by Lymph2Cx. Additionally, 5.5% of cases (n = 7) were left unclassified by Lymph2Cx, whereas they were defined as GCB (n = 4) or non-GCB (n = 3) by the Hans algorithm. Our data support the routine applicability of the Lymph2Cx assay.…
Author: | Alberto Zamò, Elena Gerhard-Hartmann, German Ott, Ioannis Anagnostopoulos, David W. Scott, Andreas Rosenwald, Hilka Rauert-WunderlichORCiD |
---|---|
URN: | urn:nbn:de:bvb:20-opus-324686 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Pathologisches Institut |
Medizinische Fakultät / Comprehensive Cancer Center Mainfranken | |
Language: | English |
Parent Title (English): | Virchows Archiv |
Year of Completion: | 2022 |
Volume: | 481 |
Issue: | 6 |
Pagenumber: | 935-943 |
Source: | Virchows Archiv (2022) 481:6, 935-943. DOI: 10.1007/s00428-022-03420-6 |
DOI: | https://doi.org/10.1007/s00428-022-03420-6 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | Hans algorithm; Lymph2Cx assay; cell of origin; diffuse large B-cell lymphoma |
Release Date: | 2024/03/11 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |